Menu Search
Equities

Orchid Pharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ORCHPHARMA:NSI

Orchid Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)663.90
  • Today's Change-6.10 / -0.91%
  • Shares traded31.91k
  • 1 Year change-29.55%
  • Beta1.4262
Data delayed at least 15 minutes, as of Feb 16 2026 10:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Orchid Pharma Ltd grew revenues 12.48% from 8.19bn to 9.22bn while net income improved 8.13% from 921.67m to 996.57m.
Gross margin39.83%
Net profit margin6.33%
Operating margin3.90%
Return on assets3.10%
Return on equity4.18%
Return on investment3.63%
More ▼

Cash flow in INRView more

In 2025, Orchid Pharma Ltd increased its cash reserves by 455.29%, or 173.05m. Cash Flow from Financing totalled 252.22m or 2.74% of revenues. In addition the company generated 192.15m in cash from operations while cash used for investing totalled 269.32m.
Cash flow per share17.16
Price/Cash flow per share38.74
Book value per share251.16
Tangible book value per share248.09
More ▼

Balance sheet in INRView more

Orchid Pharma Ltd has a Debt to Total Capital ratio of 18.11%, a higher figure than the previous year's 10.30%.
Current ratio3.35
Quick ratio1.90
Total debt/total equity0.2211
Total debt/total capital0.181
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.